In this phase 3 , 26-week , open-label , randomised trial , adults with type 2 diabetes , HbA1c of 7-10 % ( inclusive ) , a BMI of 40 kg/m ( 2 ) or less , and treated with metformin with or without pioglitazone were randomly assigned ( 2:1:1 ) to daily injections of IDegLira , insulin degludec , or liraglutide ( 18 mg per day ) .